

PRODUCT INFORMATION



LMW-PTP Inhibitor I (hydrochloride)

Item No. 22277

CAS Registry No.: 2310135-46-5
Formal Name: N,N-diethyl-4-[4-[[3-(1-piperidinyl)propyl]amino]-2-quinolinyl]-benzamide, dihydrochloride

Synonyms: LMPTP Inhibitor I,
MLS-0322825 Cmpd 23

MF: C₂₈H₃₆N₄O • 2HCl
FW: 517.5


Purity: ≥98%

UV/Vis.: λ_{max}: 220, 268, 317, 345 nm

Supplied as: A crystalline solid

Storage: -20°C

Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

LMW-PTP inhibitor I (hydrochloride) is supplied as a crystalline solid. A stock solution may be made by dissolving the LMW-PTP inhibitor I (hydrochloride) in the solvent of choice, which should be purged with an inert gas. LMW-PTP inhibitor I (hydrochloride) is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide. The solubility of LMW-PTP inhibitor I (hydrochloride) in these solvents is approximately 15, 10, and 20 mg/ml, respectively.

Further dilutions of the stock solution into aqueous buffers or isotonic saline should be made prior to performing biological experiments. Ensure that the residual amount of organic solvent is insignificant, since organic solvents may have physiological effects at low concentrations. Organic solvent-free aqueous solutions of LMW-PTP inhibitor I (hydrochloride) can be prepared by directly dissolving the crystalline solid in aqueous buffers. The solubility of LMW-PTP inhibitor I (hydrochloride) in PBS (pH 7.2) is approximately 3 mg/ml. We do not recommend storing the aqueous solution for more than one day.

Description

LMW-PTP inhibitor I (hydrochloride) is an inhibitor of low molecular weight phosphotyrosine protein phosphatase A (LMW-PTPA; IC₅₀ = 0.8 μM).¹ It is selective for LMW-PTPA over a panel of 15 protein tyrosine phosphatases but does inhibit LMW-PTPB activity by greater than 50% at 40 μM. LMW-PTP inhibitor I (hydrochloride) increases insulin-induced insulin receptor phosphorylation in HepG2 cells when used at a concentration of 10 μM. It improves glucose tolerance and decreases fasting plasma insulin levels in a mouse model of diet-induced obesity when administered at a dose of 50 mg/kg per day.

Reference

1. Stanford, S.M., Aleshin, A.E., Zhang, V., *et al.* Diabetes reversal by inhibition of the low-molecular-weight tyrosine phosphatase. *Nat. Chem. Biol.* **13**(6), 624-632 (2017).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 12/15/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM